Home - Blank Rome LLP

Register to receive insights and analyses on breaking news and trends across varying industries.
<a class="link-primary mt-4" href="/subscribe">Subscribe</a>

Philadelphia, PA

New York, NY

Wilmington, DE

Cincinnati, OH

Princeton, NJ

Los Angeles, CA

Houston, TX

Tampa, FL

Shanghai

West Palm Beach, FL

Pittsburgh, PA

Washington, D.C.

Chicago, IL

Orange County, CA

Dallas, TX

Boston, MA

Blank Rome partners <a href="/people/shannon-e-mcclure/" type="poa_person" id="18671">Shannon E. McClure</a> and <a href="/people/rachael-g-pontikes/" type="poa_person" id="18670">Rachael G. Pontikes</a> will serve as panelists at American Conference Institute’s (“ACI”) <a href="https://www.americanconference.com/glp-1-law-policy/">2nd Annual Summit on GLP-1 Law &amp; Policy</a>, being held Thursday, June 4, 2026, from 7:30 a.m. to 5:00 p.m. Blank Rome is pleased to be a Supporting Sponsor of the Summit.

core/paragraph

core/heading

The GLP-1 market is on track to reach over $30 billion by 2030. With unebbing market demand, intellectual property (“IP”) disputes, and a microscope on advertising practices, it’s critical to stay up to date on all the legislative and litigative threats facing GLP-1 manufacturers today. Industry leaders will present sessions covering everything from advertising to mass torts to peptides.

Rachael’s session, “Push for Peptides: Post-Shortage Compounding and the Peptide Gray Market,” will take place from 9:30 to 10:15 a.m.

Description: The GLP-1 market is on track to hit $33.26 billion by 2030, and innovators and compounders alike have taken notice. Post-shortage, some GLP-1 providers are searching for new ways to meet this demand. But the cutting edge comes with uncertainty, questions, and potential pitfalls.

Josh Bolin, Senior Advisor, NABP and Senior Vice President, Pulse by NABP, National Association of Boards of Pharmacy

core/list-item

Jayda Greco, Partner, McDermott Will &amp; Schulte LLP

Rachael G. Pontikes, Partner, Blank Rome LLP

core/list

Shannon’s session, “Copyright, Trademarks, and Patents: Enforcement Efforts in Intellectual Property,” will take place from 10:30 to 11:30 a.m.

Description: Intellectual property sits at the core of investment in the research and development of novel drugs. Though patents are central to IP protection, until recently copyright and trademark disputes have dominated the GLP-1 litigation landscape. As patent litigation kicks off, and semaglutide nears the end of its patent exclusivity term, understanding the baseline of GLP-1 IP protections and threats is critical to ensuring a competitive edge in the market.

Joanna T. Brougher, MPH, Esq., Owner &amp; Principal, BioPharma Law Group, PLLC

Ricardo Campello, Partner, Licks Attorneys

Shannon McClure, Partner, Blank Rome LLP

Taking Shape: The Legislative and Regulatory Landscape for GLP1s

Building Partnerships Across the GLP-1 Industry

Patient Health vs. Market Health in the GLP-1 Economy

Mass Torts, Pharmacovigilance, and Litigation Readiness

Going Viral: The Regulations, Restrictions, and Reputational Dangers of GLP-1 Advertising

Prognostication Station: Anticipating the Long Tail of the GLP-1 Market

For more information and to register, please visit the&nbsp;<a href="https://www.americanconference.com/glp-1-law-policy/">event webpage</a>.

2nd Annual Summit on GLP-1 Law & Policy

Offices

Stay Connected

Slide Menu

Slide Search

2nd Annual Summit on GLP-1 Law & Policy

Offices

Stay Connected